Progressive cholangiopathy in COVID-19 patients: Other possible diagnoses than ketamine-induced cholangiopathy should be considered.
作者信息
Deltenre Pierre, Moreno Christophe, Trépo Eric
机构信息
Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, CUB Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium; Department of Gastroenterology and Hepatology, Clinique St Luc, Bouge, Belgium.
Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, CUB Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium; Laboratory of Experimental Gastroenterology, Université Libre de Bruxelles, Brussels, Belgium.
出版信息
J Hepatol. 2021 Oct;75(4):989-990. doi: 10.1016/j.jhep.2021.02.036. Epub 2021 Mar 19.
Abstract
摘要
相似文献
1
Progressive cholangiopathy in COVID-19 patients: Other possible diagnoses than ketamine-induced cholangiopathy should be considered.新型冠状病毒肺炎患者的进行性胆管病：除氯胺酮诱发的胆管病外，还应考虑其他可能的诊断。
J Hepatol. 2021 Oct;75(4):989-990. doi: 10.1016/j.jhep.2021.02.036. Epub 2021 Mar 19.
2
Reply to: "Progressive cholangiopathy in COVID-19 patients: Other possible diagnoses than ketamine-induced cholangiopathy should be considered".回复：“COVID-19患者的进行性胆管病：除氯胺酮诱导的胆管病外，应考虑其他可能的诊断”。
J Hepatol. 2021 Oct;75(4):990-992. doi: 10.1016/j.jhep.2021.06.024. Epub 2021 Jun 24.
3
Intravenous ketamine and progressive cholangiopathy in COVID-19 patients.COVID-19患者的静脉注射氯胺酮与进行性胆管病
J Hepatol. 2021 May;74(5):1243-1244. doi: 10.1016/j.jhep.2021.02.007. Epub 2021 Feb 19.
4
Recreational ketamine-induced cholangiopathy and ulcerative cystitis.娱乐性氯胺酮诱导的胆管病和溃疡性膀胱炎。
Am J Emerg Med. 2021 Jul;45:682.e7-682.e9. doi: 10.1016/j.ajem.2020.12.025. Epub 2020 Dec 15.
5
Ketamine-induced cholangiopathy.氯胺酮诱发的胆管病。
Hong Kong Med J. 2014 Feb;20(1):78.e1-e2. doi: 10.12809/hkmj133796.
6
Consider Adjunctive Ketamine in Mechanically Ventilated Coronavirus Disease-2019 Patients.考虑在机械通气的2019冠状病毒病患者中使用辅助性氯胺酮。
J Cardiothorac Vasc Anesth. 2020 Oct;34(10):2580. doi: 10.1053/j.jvca.2020.04.037. Epub 2020 Apr 28.
7
Ketamine-induced cholangiopathy: a case report.氯胺酮诱发的胆管病：一例报告。
Am J Gastroenterol. 2011 May;106(5):1004-5. doi: 10.1038/ajg.2010.485.
8
Ketamine-induced cholangiopathy in ARDS patients.急性呼吸窘迫综合征患者中的氯胺酮诱发的胆管病
Intensive Care Med. 2021 Oct;47(10):1173-1174. doi: 10.1007/s00134-021-06482-3. Epub 2021 Jul 27.
9
Intersecting Paths of Emerging and Reemerging Infectious Diseases.新发和再发传染病的交汇路径。
Emerg Infect Dis. 2021 May;27(5):1517-1519. doi: 10.3201/eid2705.204779. Epub 2021 Mar 11.
10
Asymptomatic SARS-CoV-2-infected children attending hospital with non-COVID-19 diagnoses, March 2020-February 2021.2020年3月至2021年2月期间，因非新冠病毒疾病诊断而住院的无症状新冠病毒感染儿童。
J Infect. 2021 Aug;83(2):237-279. doi: 10.1016/j.jinf.2021.05.002. Epub 2021 May 13.
引用本文的文献
1
A Case of Hepatotoxicity Induced by Therapeutic Ketamine Use for Sedation.一例因治疗性使用氯胺酮镇静导致肝毒性的病例。
Case Rep Crit Care. 2024 Mar 12;2024:8366034. doi: 10.1155/2024/8366034. eCollection 2024.
2
Secondary Sclerosing Cholangitis After SARS-CoV2: ICU Ketamine Use or Virus-Specific Biliary Tropism and Injury in the Context of Biliary Ischemia in Critically Ill Patients?新型冠状病毒肺炎后的继发性硬化性胆管炎：危重症患者在胆汁缺血情况下使用重症监护病房氯胺酮还是病毒特异性胆管嗜性及损伤？
Hepat Med. 2023 Aug 1;15:93-112. doi: 10.2147/HMER.S384220. eCollection 2023.
3
Acute liver injury in COVID-19 patients hospitalized in the intensive care unit: Narrative review.新冠肺炎患者 ICU 住院期间的急性肝损伤：叙事性综述。
World J Gastroenterol. 2022 Dec 21;28(47):6662-6688. doi: 10.3748/wjg.v28.i47.6662.
4
Secondary sclerosing cholangitis and IgG4-sclerosing cholangitis - A review of cholangiographic and ultrasound imaging.继发性硬化性胆管炎和IgG4相关性硬化性胆管炎——胆管造影和超声成像综述
Endosc Ultrasound. 2023 Mar-Apr;12(2):181-199. doi: 10.4103/EUS-D-22-00208.
5
First report of auxiliary liver transplantation for severe cholangiopathy after SARS-CoV-2 respiratory infection.首例 SARS-CoV-2 呼吸道感染后严重胆病辅助性肝移植报告。
Am J Transplant. 2022 Dec;22(12):3143-3145. doi: 10.1111/ajt.17165. Epub 2022 Aug 17.
6
Long-term ketamine infusion-induced cholestatic liver injury in COVID-19-associated acute respiratory distress syndrome.长期输注氯胺酮诱导 COVID-19 相关急性呼吸窘迫综合征的胆汁淤积性肝损伤。
Crit Care. 2022 May 23;26(1):148. doi: 10.1186/s13054-022-04019-8.
7
Adjunctive ketamine for sedation in critically ill mechanically ventilated patients: an active-controlled, pilot, feasibility clinical trial.辅助性氯胺酮用于重症机械通气患者的镇静：一项活性对照、先导性、可行性临床试验。
J Intensive Care. 2021 Aug 30;9(1):54. doi: 10.1186/s40560-021-00569-1.
8
Liver transplantation for post-COVID-19 sclerosing cholangitis.新冠后硬化性胆管炎的肝移植。
BMJ Case Rep. 2021 Aug 26;14(8):e244168. doi: 10.1136/bcr-2021-244168.
9
Reply to: "Progressive cholangiopathy in COVID-19 patients: Other possible diagnoses than ketamine-induced cholangiopathy should be considered".回复：“COVID-19患者的进行性胆管病：除氯胺酮诱导的胆管病外，应考虑其他可能的诊断”。
J Hepatol. 2021 Oct;75(4):990-992. doi: 10.1016/j.jhep.2021.06.024. Epub 2021 Jun 24.
Zotero 插件